Atea Pharmaceuticals, Inc.
NASDAQ:AVIRBiotechnology
-$0.04 today
- Market cap
- $320.41M
- Beta
- 0.32
- P/E (TTM)
- -2.0
- EPS (TTM)
- -$2.14
Volume 0.34M
Average 0.34M
AVIR Long-term Debt
Borrowings due after more than one year.
Atea Pharmaceuticals, Inc.NASDAQ: AVIR
Long-term Debt · Q1 FY2026 · quarter ended Mar 2026
Long-term debt remains negative
Q1 FY2026 long-term debt was $0, compared with $0 a year earlier.
Context
- Long-term debt amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Long-term debt increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Long-term Debt history
USD · from the balance sheet
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Long-term Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Long-term Debt vs competitors
How AVIR compares with its peers on the latest reported figures
- AVIR's Mar 2026 long-term debt of $0 is the 4th highest of the 5 companies compared; the peer median is $44.27M.
- Long-term debt amounts to 0.0% of total assets for AVIR, versus a peer median of 4.6%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $98.62M | -22.2% | +329.1% | 31.3% | |
| Mar 2026 | $86.64M | — | — | 8.4% | |
| Mar 2026 | $1.9M | — | — | 0.8% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | -100.0% | -30.8% | 0.0% | |
| Peer median (excluding AVIR) | $44.27M | -61.1% | +149.2% | 4.6% | |
Competitors are the stored peer set for AVIR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 764.38M | 646.71M | 143.82M | 64.7M | 95.71M |
| Short-term Investments | 0 | 0 | 434.28M | 390.03M | 206.12M |
| Net Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | (0) | 14.21M | 12.35M | 7.63M | 9.16M |
| Total Current Assets | 772.4M | 660.92M | 590.46M | 462.36M | 310.99M |
| Property, Plant & Equipment (Net) | 184K | 4.09M | 3.12M | 2.12M | 1.09M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 305K | 198K | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 0 | 1.49M | 1.4M | 197K | 3.14M |
| Total Non-current Assets | 489K | 5.79M | 4.51M | 2.31M | 4.23M |
| Total Assets | 772.89M | 666.71M | 594.97M | 464.67M | 315.22M |
| Account Payables | 4.53M | 2.55M | 4.25M | 4.46M | 12.95M |
| Short-term Debt | 0 | 0 | 0 | 0 | 843K |
| Tax Payables | 0 | 99K | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 27.57M | 8.65M | 0 | 7.44M | 19.56M |
| Total Current Liabilities | 56.88M | 18.48M | 32.38M | 18.6M | 39.78M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 5.93M | 5.26M | 5.76M | 6.36M | 0 |
| Total Non-current Liabilities | 5.93M | 7.66M | 7.4M | 7.2M | 0 |
| Total Liabilities | 62.82M | 26.14M | 39.78M | 25.8M | 39.78M |
| Common Stock | 83K | 83K | 83K | 84K | 78K |
| Retained Earnings | 56.03M | (59.88M) | (195.84M) | (364.22M) | (522.57M) |
| Accumulated OCI | (0) | (684K) | 207K | 233K | 174K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 710.08M | 640.57M | 555.19M | 438.87M | 275.43M |
| Total Debt | 197K | 3.12M | 2.4M | 1.64M | 843K |
| Net Debt | (764.18M) | (643.59M) | (141.42M) | (63.05M) | (94.87M) |
Atea Pharmaceuticals, Inc.
NASDAQ:AVIR
Intrinsic Alpha fair value
Locked
Current Price
$3.99
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.